About InVivoSIM anti-human IL‑3RA (CD123) (Pivekimab Biosimilar) This biosimilar antibody uses the same variable regions as the therapeutic antibody Pivekimab, making it ideal for research use. Pivekimab is a humanized IgG1 monoclonal antibody that specifically targets CD123, also known as interleukin‑3 receptor alpha (IL‑3RA). CD123 is highly expressed on malignant hematopoietic cells, including acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), and plays a critical role in IL‑3–mediated cell survival and proliferation. By binding to CD123, Pivekimab blocks IL‑3 signaling pathways involved in the pathogenesis of myeloid malignancies. While the therapeutic version (pivekimab sunirine) is conjugated to a cytotoxic payload, this Pivekimab biosimilar is unconjugated and intended for research use only. It is well suited for studying IL‑3 signaling, CD123 expression, and receptor blockade in hematologic cancers. InVivoSIM anti-human IL‑3RA (CD123) (Pivekimab Biosimilar) Specifications IsotypeHuman IgG1, κ Recommended Isotype Control(s)RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman IL‑3RA Reported Applicationsin vivo functional assays in vitro functional assays Flow cytometry ELISA FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
